ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.90
-0.22%
Dow Jones
40,954.48
1.85%
Gold vs US Dollar
2,466.69
1.84%
Brent Oil
83.245
-1.30%
Bitcoin
65,149.98
0.46%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) News

Nuvalent (NUVL)

Nuvalent Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NUVL
DateTimeSourceHeadlineSymbolCompany
16/07/202411:30PR Newswire (US)Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024NASDAQ:NUVLNuvalent Inc
11/07/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
11/07/202421:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
11/07/202411:30PR Newswire (US)Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific OfficerNASDAQ:NUVLNuvalent Inc
10/07/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
08/07/202421:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
18/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
14/06/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
14/06/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
14/06/202421:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
14/06/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
14/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
07/06/202421:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
29/05/202421:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
29/05/202411:30PR Newswire (US)Nuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
17/05/202421:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
16/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
16/05/202421:01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
15/05/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/05/202411:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
09/05/202411:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
09/05/202411:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/05/202421:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
08/04/202421:30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202421:52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202412:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202411:42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
27/02/202411:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
27/02/202411:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NUVLNuvalent Inc
27/02/202411:15PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520NASDAQ:NUVLNuvalent Inc
 Showing the most relevant articles for your search:NASDAQ:NUVL

Your Recent History

LSE
EIMI
Ishrc Em Imi
NASDAQ
CATY
Cathay General Bancorp
BOV
SEED13
Seedel Tecnologia Ltda
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved